Search

Displaying results 2171 - 2180 of 10000 in total
  1. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.

    Mixtures: GENVOYA FILM COATED TABLET 150 MG/150 MG/200 MG/10 MG, STRIBILD FILM COATED TABLET 150 MG/150 MG/200 MG/245 MGCategories: Antivirals used in combination for the treatment of HIV infections
  2. Indication

    Tuberous Sclerosis Complex with Renal angiomyolipoma

    go.drugbank.com/conditions/DBCOND0025534
    Drugs: Everolimus
    Synonyms: Tuberous Sclerosis Complex with Renal angiomyolipoma
  3. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    Eurartesim was first authorized for market by the European Medicines Agency in October 2011. … It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label].

    Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS
  4. Drug

    Pixantrone

    go.drugbank.com/drugs/DB06193
    ApprovedWithdrawn

    Another phase III trial, PIX-R, is now ongoing to clarify pixantrones place in therapy. It will compare pixantrone efficacy to that of gemcitabine. [2] … It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union

    Synonyms: 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
  5. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.

  6. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]

    Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
  7. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose … in mice) studies.

  8. Drug

    Padimate O

    go.drugbank.com/drugs/DB11570
    Approved

    Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153]. … It penetrates human skin, and is shown to induce non-ligatable strand breaks on DNA _in vitro_ and mutagenic effects on yeast i_n vivo_ [A32458].

    Mixtures: Banana Boat Sunscreen Oil Spray Huile Écran Solaire En Vaporisateur SPF Fps 4, Banana Boat Sunscreen Oil Spray Huile Ecran Solaire En Vaporisateur SPF Fps 15Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  10. Target

    Copper-containing nitrite reductase

    go.drugbank.com/bio_entities/BE0001495
    TargetAchromobacter cycloclastes

    Polypeptides: Copper-containing nitrite reductaseFunction: copper ion binding